Melanoma/Skin Cancer

Top Story

Multiple primary melanomas most likely in first year after initial melanoma diagnosis

August 26, 2015

The risk for multiple primary melanomas was greatest in the first year after initial melanoma diagnosis, with patients who were older, male, white and partnered being at higher risk, according to recently published study results.

Researchers estimated multiple primary melanoma incidence among 16,570 Kaiser Permanente Northern California members diagnosed with melanoma between 1996 and 2011. Characteristics of patients with multiple primary melanomas and single primary melanomas were compared.

Vernon K. Sondak, MD

Interim DeCOG results provide reassurance for patients who delay CLND after positive sentinel node

HemOnc Today, August 25
Vernon K. Sondak, MD
The majority of patients with stage III melanoma present with a positive sentinel lymph node in a clinically negative regional basin.Because nodal disease is being…
Lorenzo Cohen, PhD

Stress and cancer: Mindfulness is pivotal component to improve outcomes

August 24, 2015
Stress hormones are released when the body responds to physical, mental or emotional pressures.These stress hormones — such as epinephrine and
In the Journals

Immune-related adverse events do not impact melanoma survival, time to treatment failure

August 21, 2015
Patients with melanoma treated with ipilimumab often experience immune-related adverse events; however, these events do not appear to impact patient survival or time to…
CME
Hematology Oncology Case Consults

The Patient with Melanoma

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with melanoma.
More »
Meeting News Coverage Video
VIDEO: Patients with albinism have advanced skin cancer risk

VIDEO: Patients with albinism have advanced skin cancer risk

June 18, 2015
VANCOUVER — In this video, Roderick Hays, MD, FRCP, discusses risks facing patients with albinism, including…
More »
CME
PD-1 Antibodies

PD-1 Antibodies

This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc., Merck & Co., Inc., OncoSec Medical, Inc., Prometheus and Provectus Pharmaceuticals, Inc.

This activity will review data on the efficacy, safety, and response patterns observed with PD-1 in patients with…
More »
In the Journals

Multiple primary melanomas most likely in first year after initial melanoma diagnosis

August 26, 2015
The risk for multiple primary melanomas was greatest in the first year after initial melanoma diagnosis, with patients who were older, male, white…
Vernon K. Sondak, MD

Interim DeCOG results provide reassurance for patients who delay CLND after positive sentinel node

HemOnc Today, August 25
Vernon K. Sondak, MD
The majority of patients with stage III melanoma present with a positive sentinel lymph node in a clinically negative regional basin.Because nodal…
Lorenzo Cohen, PhD

Stress and cancer: Mindfulness is pivotal component to improve outcomes

August 24, 2015
Stress hormones are released when the body responds to physical, mental or emotional pressures.These stress hormones — such as epinephrine and…
In the Journals

Immune-related adverse events do not impact melanoma survival, time to treatment failure

August 21, 2015
Patients with melanoma treated with ipilimumab often experience immune-related adverse events; however, these events do not appear to impact patient…
Carolyn C. Kim Meeting News Coverage

Fewer moles may be associated with more aggressive melanoma

August 20, 2015
People with fewer moles may be more at risk for aggressive melanoma than people with many moles, according to research being presented at the…

Enrollment begins in Keytruda, ImmunoPulse IL-12 phase 2 melanoma trial

August 19, 2015
OncoSec Medical announced enrollment has begun in a phase 2 trial, led by University of California, San Francisco, of the company’s ImmunoPulse…
Roger M. Perlmutter, MD, PhD FDA News

FDA grants priority review to Keytruda for first-line treatment of advanced melanoma

August 19, 2015
The FDA granted priority review to pembrolizumab for the first-line treatment of patients with unresectable or metastatic melanoma, according to a…
In the Journals

Immunosuppression, older age linked to higher risk for aggressive melanoma

August 18, 2015
Researchers found that older patients and patients with immunosuppression are at higher risk for aggressive melanoma, according to recent…
Michael A. Henderson, MD, FRACS In the Journals

Long-term data clarify role of adjuvant radiotherapy after lymphadenectomy for melanoma

August 13, 2015
Adjuvant radiation to the lymph-node field after lymphadenectomy significantly reduced the rate of lymph-node field relapse without an OS improvement…
In the Journals

Vinblastine effective in patients with relapsing multifocal cutaneous anaplastic large cell lymphoma

August 12, 2015
Patients with relapsing cutaneous anaplastic large cell lymphoma responded to vinblastine as a single-agent chemotherapy, according to recent study…
More Headlines »
morganatic-roan
morganatic-roan